Portola Pharma (PTLA) Gets Credit Suisse Higher Rating; Last Week KVH Industries, Inc. (KVHI) Coverage

August 27, 2017 - By Vivian Currie

Among 3 analysts covering KVH Industries (NASDAQ:KVHI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. KVH Industries had 5 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Raymond James on Tuesday, March 28. The firm has “Buy” rating given on Wednesday, August 5 by Zacks. Needham maintained KVH Industries, Inc. (NASDAQ:KVHI) on Wednesday, November 4 with “Buy” rating. Needham maintained the stock with “Buy” rating in Wednesday, August 5 report. The stock of KVH Industries, Inc. (NASDAQ:KVHI) earned “Neutral” rating by Chardan Capital Markets on Tuesday, May 31. See KVH Industries, Inc. (NASDAQ:KVHI) latest ratings:

28/03/2017 Broker: Raymond James Old Rating: Strong Buy New Rating: Outperform Downgrade

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals has $8000 highest and $24 lowest target. $66.33’s average target is 16.70% above currents $56.84 stock price. Portola Pharmaceuticals had 25 analyst reports since August 5, 2015 according to SRatingsIntel. As per Sunday, July 23, the company rating was maintained by Oppenheimer. Credit Suisse maintained the shares of PTLA in report on Tuesday, December 27 with “Outperform” rating. As per Monday, June 26, the company rating was maintained by Morgan Stanley. The firm has “Buy” rating given on Thursday, August 10 by Oppenheimer. As per Monday, March 28, the company rating was maintained by Credit Suisse. The firm has “Neutral” rating by Citigroup given on Friday, August 19. The firm has “Outperform” rating given on Thursday, August 24 by Credit Suisse. As per Monday, June 26, the company rating was maintained by Cowen & Co. Morgan Stanley maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Friday, August 19. Morgan Stanley has “Overweight” rating and $28 target. The firm has “Buy” rating by Citigroup given on Friday, May 27.

The stock increased 1.82% or $0.2 on August 25, reaching $11.2. About 15,773 shares traded. KVH Industries, Inc. (NASDAQ:KVHI) has risen 16.54% since August 27, 2016 and is uptrending. It has underperformed by 0.16% the S&P500.

Investors sentiment increased to 1.71 in 2016 Q4. Its up 0.09, from 1.62 in 2016Q3. It increased, as 1 investors sold KVH Industries, Inc. shares while 25 reduced holdings. 15 funds opened positions while 27 raised stakes. 10.77 million shares or 1.54% more from 10.61 million shares in 2016Q3 were reported. Jacobs Levy Equity Management has 28,410 shares. 579 were reported by Panagora Asset Mgmt Inc. Geode Cap Limited Liability Corporation reported 0% in KVH Industries, Inc. (NASDAQ:KVHI). Prelude Cap Mgmt Lc holds 0% or 3,183 shares in its portfolio. Kcg Hldgs Inc accumulated 14,693 shares or 0% of the stock. 18,000 are owned by Pnc Fincl Service Gp Incorporated. Citigroup holds 0% of its portfolio in KVH Industries, Inc. (NASDAQ:KVHI) for 31,684 shares. Blackrock has invested 0% in KVH Industries, Inc. (NASDAQ:KVHI). Fincl Bank Of Ny Mellon Corporation reported 0% of its portfolio in KVH Industries, Inc. (NASDAQ:KVHI). Sei Invests has 88 shares. Signia Cap Mgmt Limited Com reported 2.27% of its portfolio in KVH Industries, Inc. (NASDAQ:KVHI). Thomson Horstmann And Bryant stated it has 121,854 shares or 0.18% of all its holdings. Schwab Charles Investment Mngmt holds 30,800 shares. Globeflex Capital L P reported 0% stake. Morgan Stanley holds 0% of its portfolio in KVH Industries, Inc. (NASDAQ:KVHI) for 49,501 shares.

KVH Industries, Inc. is a manufacturer of solutions that provide high-speed Internet, television and voice services through satellite to mobile users at sea and on land. The company has market cap of $191.39 million. The Firm also provides commercially licensed entertainment, including news, sports, music and movies, to commercial and leisure clients in the maritime, hotel and retail markets. It currently has negative earnings. It operates in two geographic divisions, in the mobile communications, navigation and guidance and stabilization equipment industry.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.28 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

The stock decreased 3.97% or $2.35 on August 25, reaching $56.84. About 784,222 shares traded or 3.82% up from the average. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since August 27, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Investors sentiment increased to 1.6 in Q4 2016. Its up 0.55, from 1.05 in 2016Q3. It is positive, as 17 investors sold Portola Pharmaceuticals Inc shares while 42 reduced holdings. 17 funds opened positions while 45 raised stakes. 48.44 million shares or 1.23% less from 49.04 million shares in 2016Q3 were reported. Blair William & Il invested in 0% or 20,621 shares. United Automobile Association holds 0.01% or 121,834 shares in its portfolio. New York-based Joel Isaacson & Ltd Llc has invested 0.01% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Barclays Public invested in 0% or 28,319 shares. Blackrock Institutional Tru Na has 0% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 1.47M shares. California Public Employees Retirement System, a California-based fund reported 40,700 shares. Rhumbline Advisers reported 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Pinnacle Associate invested 0.25% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Moreover, Brown Brothers Harriman has 0% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Loring Wolcott Coolidge Fiduciary Advisors Limited Liability Partnership Ma, a Massachusetts-based fund reported 10 shares. Wellington Mgmt Group Llp stated it has 0.03% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). 332,797 are held by Citadel Advisors Ltd Company. Oxford Asset Mngmt has invested 0.06% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). 24,500 are owned by Pacad. Deerfield Management holds 4.3% or 4.65M shares in its portfolio.

Since March 1, 2017, it had 1 buying transaction, and 6 selling transactions for $58.31 million activity. The insider HOMCY CHARLES J sold 50,000 shares worth $2.00M. BIRD JEFFREY W also bought $3.80 million worth of Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Wednesday, May 31. Another trade for 1.70M shares valued at $58.48M was made by Maxwell (Mauritius) Pte Ltd on Thursday, June 1. On Monday, April 10 the insider Fu Tao sold $40,556. 10,235 shares were sold by Dier Mardi, worth $409,605 on Wednesday, March 15. 6,750 shares were sold by Lis William, worth $243,405 on Tuesday, April 11.